| pubmed-article:19762222 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19762222 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19762222 | lifeskim:mentions | umls-concept:C0024501 | lld:lifeskim |
| pubmed-article:19762222 | lifeskim:mentions | umls-concept:C0032893 | lld:lifeskim |
| pubmed-article:19762222 | lifeskim:mentions | umls-concept:C0439858 | lld:lifeskim |
| pubmed-article:19762222 | lifeskim:mentions | umls-concept:C1276807 | lld:lifeskim |
| pubmed-article:19762222 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:19762222 | pubmed:dateCreated | 2009-10-5 | lld:pubmed |
| pubmed-article:19762222 | pubmed:abstractText | Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) reduces asthma exacerbations and symptoms versus fixed-dose regimens plus short-acting beta(2)-agonists (SABA) in double-blind trials. Information is lacking regarding its effectiveness versus conventional best practice (CBP). This pooled analysis of six 6-month, randomized, open-label studies examined asthma control and exacerbation risk in asthmatics (aged> or =12 years). Patients (N=7855) symptomatic on inhaled corticosteroids (ICS) or stable/symptomatic on ICS/long-acting beta(2)-agonists (LABA) received budesonide/formoterol maintenance and reliever therapy (160/4.5microg bid and as needed) or CBP (ICS or ICS/LABA+/-other agents at an approved dose plus as-needed SABA). Overall asthma control was assessed comparing the incidence of exacerbations and levels of asthma control using the asthma control questionnaire (ACQ). Budesonide/formoterol maintenance and reliever therapy did not significantly reduce time to first severe exacerbation (primary variable) versus CBP (P=0.062). However, patients in this group experienced 15% fewer exacerbations (0.20 versus 0.24/patient/year; P=0.021) and used 27% less ICS (P<0.0001). Odds of remaining well controlled (ACQ< or =0.75) over 6 months were higher with budesonide/formoterol maintenance and reliever therapy versus CBP (45% versus 41%, odds ratio [OR] 1.29; P<0.01) while risk of remaining uncontrolled decreased (25% versus 29%, OR 0.81; P<0.01). Budesonide/formoterol maintenance and reliever therapy improves key aspects of asthma control versus physicians' choice of CBP. | lld:pubmed |
| pubmed-article:19762222 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19762222 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19762222 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19762222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19762222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19762222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19762222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19762222 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19762222 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19762222 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19762222 | pubmed:issn | 1532-3064 | lld:pubmed |
| pubmed-article:19762222 | pubmed:author | pubmed-author:NayaIanI | lld:pubmed |
| pubmed-article:19762222 | pubmed:author | pubmed-author:DemolyPascalP | lld:pubmed |
| pubmed-article:19762222 | pubmed:author | pubmed-author:SearsMalcolm... | lld:pubmed |
| pubmed-article:19762222 | pubmed:author | pubmed-author:LouisRenaudR | lld:pubmed |
| pubmed-article:19762222 | pubmed:author | pubmed-author:WorthHeinrich... | lld:pubmed |
| pubmed-article:19762222 | pubmed:author | pubmed-author:AlmeidaJoaoJ | lld:pubmed |
| pubmed-article:19762222 | pubmed:author | pubmed-author:Søes-Petersen... | lld:pubmed |
| pubmed-article:19762222 | pubmed:author | pubmed-author:CarlsheimerAs... | lld:pubmed |
| pubmed-article:19762222 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19762222 | pubmed:volume | 103 | lld:pubmed |
| pubmed-article:19762222 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19762222 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19762222 | pubmed:pagination | 1623-32 | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:meshHeading | pubmed-meshheading:19762222... | lld:pubmed |
| pubmed-article:19762222 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19762222 | pubmed:articleTitle | Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. | lld:pubmed |
| pubmed-article:19762222 | pubmed:affiliation | University Hospital of Montpellier and INSERM U, Hôpital Arnaud de Villeneuve, France. pascal.demoly@inserm.fr | lld:pubmed |
| pubmed-article:19762222 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19762222 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19762222 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
